Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
EPTIFIBATIDE
OMEGA LABORATORIES LIMITED
B01AC16
EPTIFIBATIDE
2MG
SOLUTION
EPTIFIBATIDE 2MG
INTRAVENOUS
100ML
Prescription
PLATELET AGGREGATION INHIBITORS
Active ingredient group (AIG) number: 0137621002; AHFS:
APPROVED
2013-08-08
1 PRODUCT MONOGRAPH Pr EPTIFIBATIDE INJECTION Intravenous Solution 2 mg/mL bolus Injection 0.75 mg/mL Injection (as infused) PLATELET AGGREGATION INHIBITOR Omega Laboratories Ltd. 11 177 Hamon Street Montréal, Québec H3M 3E4 Date of Revision: July 29, 2013 Control # : 157026 2 PRODUCT MONOGRAPH Pr EPTIFIBATIDE INJECTION PLATELET AGGREGATION INHIBITOR ACTION AND CLINICAL PHARMACOLOGY GENERAL: Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive ligands to glycoprotein IIb/IIIa (GP IIb/IIIa). When administered intravenously, eptifibatide inhibits _ex vivo _platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of eptifibatide; this is thought to result from dissociation of eptifibatide from the platelet receptor. PHARMACODYNAMICS: Eptifibatide inhibits platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide is observed immediately after administration of a 180 μg/kg intravenous bolus. When followed by a 2.0 μg/kg/min continuous infusion, this regimen produces a >80% inhibition of 20 μM ADP-induced _ ex vivo _ platelet aggregation, (at physiologic calcium concentrations) in more than 80% of patients, after more than 8 hours of infusion. Platelet inhibition was reversed, with a >50% return of platelet function towards baseline 4 hours after discontinuation of an infusion of 2.0 μg/kg/min. The eptifibatide dosing regimen used in the ESPRIT study was similar to that used in the PURSUIT study (a 180 μg/kg bolus followed by a 2.0 μg/kg/min infusion), but added a second 180 μg/kg bolus ten minutes after the first bolus to avoid a transient decrease in platelet aggregation inhibition before reaching steady-state with the continuous 2.0 μg/kg/min infusion. This dosing regimen is recommended in order to maintain platelet aggregation inhibition above 80% in the Baca dokumen lengkapnya